CareDx, Inc. (CDNA)
NASDAQ: CDNA · Real-Time Price · USD
21.50
+0.69 (3.32%)
At close: May 1, 2026, 4:00 PM EDT
21.71
+0.21 (0.98%)
After-hours: May 1, 2026, 7:03 PM EDT
CareDx Revenue
CareDx had revenue of $117.70M in the quarter ending March 31, 2026, with 38.99% growth. This brings the company's revenue in the last twelve months to $412.82M, up 19.17% year-over-year. In the year 2025, CareDx had annual revenue of $379.81M with 13.79% growth.
Revenue (ttm)
$412.82M
Revenue Growth
+19.17%
P/S Ratio
2.69
Revenue / Employee
$539,634
Employees
765
Market Cap
1.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 379.81M | 46.02M | 13.79% |
| Dec 31, 2024 | 333.79M | 53.46M | 19.07% |
| Dec 31, 2023 | 280.32M | -41.47M | -12.89% |
| Dec 31, 2022 | 321.79M | 25.40M | 8.57% |
| Dec 31, 2021 | 296.40M | 104.20M | 54.22% |
| Dec 31, 2020 | 192.19M | 65.13M | 51.25% |
| Dec 31, 2019 | 127.07M | 50.50M | 65.95% |
| Dec 31, 2018 | 76.57M | 28.25M | 58.45% |
| Dec 31, 2017 | 48.32M | 7.69M | 18.93% |
| Dec 31, 2016 | 40.63M | 12.49M | 44.37% |
| Dec 31, 2015 | 28.14M | 838.00K | 3.07% |
| Dec 31, 2014 | 27.31M | 5.21M | 23.57% |
| Dec 31, 2013 | 22.10M | 1.65M | 8.05% |
| Dec 31, 2012 | 20.45M | 17.51M | 595.14% |
| Dec 31, 2006 | 2.94M | 2.62M | 799.69% |
| Dec 31, 2005 | 327.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Myriad Genetics | 824.50M |
| NeoGenomics | 745.97M |
| OPKO Health | 581.12M |
| Veracyte | 517.15M |
| GeneDx Holdings | 427.54M |
| Twist Bioscience | 391.56M |
| Castle Biosciences | 344.23M |
| Fulgent Genetics | 320.35M |
CDNA News
- 2 days ago - CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 days ago - CareDx Earnings Call Transcript: Q1 2026 - Transcripts
- 5 days ago - CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing - Business Wire
- 5 days ago - CareDx Announces First Quarter 2026 Financial Results - Business Wire
- 12 days ago - CareDx Announces Presentation of More Than 50 Abstracts Including 16 Oral Presentations at the International Society for Heart and Lung Transplantation's 46th Annual Meeting - Business Wire
- 13 days ago - CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing - Business Wire
- 17 days ago - CareDx Sharpens Focus On Core Testing Services - Benzinga
- 17 days ago - Eurobio scientific signs definitive agreement to acquire CareDx's transplant Lab Product division - GlobeNewsWire